Grasil (Sildenafil)

Grasil is primarily used in clinical practice for conditions that benefit from enhanced blood flow mediated by PDE5 inhibition.

• Treatment of erectile dysfunction in adult males.
• Management of pulmonary arterial hypertension in settings where off‑label use is permitted.
• Investigational application in certain cardiovascular disorders where vasodilation is desired.
• Adjunct therapy for selected patients with benign prostatic hyperplasia who also experience sexual dysfunction.

Like other sildenafil‑containing products, Grasil may be associated with a range of adverse effects that vary in frequency and severity.

Common

• Headache, often described as mild to moderate.
• Flushing or warmth in the face and upper chest.
• Indigestion or dyspepsia.
• Nasal congestion or a runny nose.
• Visual disturbances such as a blue‑tinted vision.

Serious

• Sudden loss of vision (non‑arteritic anterior ischemic optic neuropathy).
• Sudden loss of hearing or ringing in the ears.
• Prolonged erection lasting more than four hours (priapism).
• Severe hypotension, especially when combined with nitrates.
• Cardiovascular events such as myocardial infarction or stroke in high‑risk individuals.

Patients should consider several safety factors before starting Grasil, and ongoing monitoring may be required.

• Evaluate cardiovascular health, particularly in patients with known heart disease.
• Avoid use in individuals taking nitrates or nitric‑oxide donors due to risk of severe hypotension.
• Use caution in patients with severe liver or kidney impairment, as drug clearance may be altered.
• Discuss any history of retinal disorders or sudden vision loss with a healthcare professional.
• Inform the prescriber of any prior episodes of priapism or prolonged erections.
• Pregnant or breastfeeding individuals should not use Grasil, as safety has not been established.

Grasil can interact with several medication classes, influencing its efficacy or safety profile.

Avoid

• Nitrates (e.g., nitroglycerin, isosorbide dinitrate) because of additive blood‑pressure lowering effects.
• Certain potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) which can increase sildenafil concentrations.

Use with caution

• Alpha‑blockers (e.g., tamsulosin) due to possible additive hypotensive effects.
• Other antihypertensive agents, especially when dose‑adjusted.
• Medications that affect QT interval, although the risk is low.
• Herbal supplements such as St John’s wort that may alter CYP3A4 activity.